Centre Reduces Anti-Cancer Drug Prices as Supreme Court Questions Scope of Trade Margin Caps

The central government has revised maximum retail prices for 543 anti-cancer drug brands following a 30 per cent trade margin cap implemented by the National Pharmaceutical Pricing Authority. According to the reported details, generic and biosimilar medicines are set to see price cuts of up to 93 per cent, taking effect from November 9.

Meanwhile, the Supreme Court has reserved its order while examining the disparity between retailer costs and retail prices. The court questioned why trade margin caps cannot be extended to other essential medicines.

State-Level Transparency Measures

• Karnataka Directive: The Karnataka government has mandated that hospitals disclose both purchase costs and maximum retail prices on patient bills starting November 1.
• Objective: The measure aims to improve billing transparency for patients across the state.

Practical Implications and Verification

Patients and healthcare consumers can verify updated drug pricing through official notifications issued by the National Pharmaceutical Pricing Authority or by reviewing updated retail price lists at licensed pharmacies. To confirm hospital billing changes, individuals can consult the official notifications released by the Karnataka state health department or request itemized bills displaying purchase costs alongside maximum retail prices as mandated.